NCGC00138783 (TFA)

NCGC00138783 TFA is a selective inhibitor targeting CD47/SIRPα axis, with an IC50 of 50 μM. NCGC00138783 TFA directly blocks the interaction between CD47 and SIRPα axis[1][2].

Product Specifications

UNSPSC

12352005

Target

CD47

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ncgc00138783-tfa.html

Purity

99.38

Solubility

DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(C(F)(F)F)O.CCC(C(NC1=CC=C(C=C1)F)=O)SC2=NC3=C(C4=NC(CCC5=C(NN=C5C)C)=NN24)C=CC=C3

Molecular Formula

C28H27F4N7O3S

Molecular Weight

617.62

References & Citations

[1]Junqiao Zhu, et al. CD47-SIRPα axis in cancer therapy: Precise delivery of CD47-targeted therapeutics and design of anti-phagocytic drug delivery systems. Medicine in Drug Discovery. 2022. 15:100139|[2]Bo Huang, et al. Structural analysis and binding sites of inhibitors targeting the CD47/SIRPα interaction in anticancer therapy. Comput Struct Biotechnol J. 2021 Oct 1;19:5494-5503.